- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06027788
CTSN 색전증 보호 시험 (EMPRO)
고위험 판막 수술을 받는 환자의 색전 보호
This is a prospective, multi-center, randomized effectiveness trial of the CardioGard Embolic Protection Cannula in high-risk valve surgery patients.
연구 개요
상태
상세 설명
This is a prospective, multicenter, randomized controlled clinical trial that will evaluate the effectiveness and safety of the CardioGard embolic protection cannula compared to a standard cannula. The enrollment period is expected to last 30 months, and all patients will be followed for 12 months post procedure.
RANDOMIZATION Patients will be randomized 1:1 to the embolic protection device or to a standard cannula in the operating room (OR) immediately after sternotomy and confirmation by the surgical team of the patient's suitability for the proposed intervention (CardioGard embolic protection device). Randomization will be with equal allocation and stratified by site and by procedure (i.e., isolated valve surgery or combined procedures, such as double valve or valve plus coronary artery bypass grafting, CABG). The randomization assignment will be controlled centrally and performed through a web-based data collection system that automates the delivery of the randomization codes. From the point of treatment assignment, primary efficacy will be analyzed by intention-to-treat; that is, the patients will be grouped by their assignments at randomization regardless of whether or not they actually received the treatment to which they were assigned.
STUDY POPULATION The patient population for this trial consists of patients age ≥ 60 undergoing different types of valve surgery with or without CABG via full or minimal-access sternotomy using legally marketed valve(s). Specific inclusion and exclusion criteria are listed below. All patients who meet the eligibility criteria may be included in the study regardless of gender, race, or ethnicity.
SUBSTUDY Sleep Disturbance Ancillary Sub-Study - Patients undergoing surgery for valvular heart disease (VHD) are at high risk for adverse events, including high rates of post-operative delirium (POD). Should circadian disruption be found to be an important predictor in this high-risk population, safe, low cost, and easy to administer therapies to regulate circadian rhythm such as light therapy could be evaluated in future studies
The aims of this ancillary sub-study include:
- To investigate the association between short sleep duration, less sleep regularity, and greater circadian rhythm disruption prior to surgery and POD within 7 days of VHD surgery.
- To investigate the association between short sleep duration, less sleep regularity and greater circadian rhythm disruption (reduced melatonin and cortisol amplitudes) after surgery and POD within 7 days of VHD surgery.
Approximately 300 EMPRO trial participants will be enrolled into the ancillary study. The study is being conducted in highly experienced clinical centers in the U.S. and Canada. The estimated enrollment period is 12-15 months.
All eligible and consented patients in the parent EMPRO trial will be offered enrollment in this ancillary study through the parent trial consent process.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Arkansas
-
North Little Rock, Arkansas, 미국, 72117
- CHI St. Vincent Heart Institute
-
-
California
-
Los Angeles, California, 미국, 90033
- Keck Hospital of the University of Southern California
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322
- Emory University
-
-
Louisiana
-
New Orleans, Louisiana, 미국, 70506
- Ochsner Clinic
-
-
Maine
-
Portland, Maine, 미국, 04102
- Maine Medical Center
-
-
Maryland
-
Baltimore, Maryland, 미국, 21287
- Johns Hopkins Medicine
-
College Park, Maryland, 미국, 20742
- University of Maryland
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02114
- Massachusetts General Hospital
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- University of Michigan
-
-
Minnesota
-
Rochester, Minnesota, 미국, 55905
- Mayo Clinic
-
-
Missouri
-
Kansas City, Missouri, 미국, 64111
- Saint Luke's Hospital of Kansas City
-
-
New York
-
New York, New York, 미국, 10032
- Columbia University Medical Center
-
New York, New York, 미국, 21287
- Northwell Health
-
The Bronx, New York, 미국, 10467
- Montefiore Medical Center
-
-
North Carolina
-
Durham, North Carolina, 미국, 27710
- Duke University
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45267
- University of Cincinnati Medical Center
-
Cleveland, Ohio, 미국, 44195
- Cleveland Clinic
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19104
- Hospital of the University of Pennsylvania
-
-
Virginia
-
Charlottesville, Virginia, 미국, 22903
- University of Virginia
-
-
West Virginia
-
Morgantown, West Virginia, 미국, 26506
- West Virginia University
-
-
-
-
Ontario
-
London, Ontario, 캐나다
- London Health Sciences Centre
-
Ottawa, Ontario, 캐나다
- University of Ottawa Heart Institute
-
-
Quebec
-
Montreal, Quebec, 캐나다
- Montreal Heart Institute
-
Québec, Quebec, 캐나다, QC G1V 4G5
- Hôpital Laval
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Age ≥ 60 years
-
Planned de novo or redo:
- Surgical aortic valve replacement SAVR ± ascending aortic repair (if circulatory arrest is not required) ± CABG
- Mitral valve replacement (MVR) ± CABG
- Mitral Valve Repair + CABG,
- Double/Triple valve surgery ± CABG; Ross procedure These procedures can be done via a full or minimal-access sternotomy (using central aortic perfusion cannulae) with legally marketed valve(s), and can be done in combination with an left atrial appendage (LAA) closure/excision or partial/complete Maze procedure.
- Valve sparing aortic root replacement (David procedure)
- Valve sparing aortic root replacement (David procedure)
-
No evidence of neurological impairment as defined by a NIHSS ≤1 and modified Rankin scale (mRS) ≤2 within 30 days prior to randomization
-
Ability to provide informed consent and comply with the protocol
Exclusion Criteria:
- History of clinical stroke within 3 months prior to randomization
- Cerebral and or aortic arch arteriography or interventions within 3 days of the planned procedure
- Coronary catheterization within 3 days of index procedure, and the required repeat NIHSS score post-catheterization is worse than the screening/baseline NIHSS score conducted prior to the catheterization
- Active endocarditis at time of randomization with vegetation criteria
- Clinical signs of cardiogenic shock or treatment with IV inotropic therapy prior to randomization
- Participation in an interventional (drug or device) trial
- Isolated mitral valve repair, isolated tricuspid valve repair or combined mitral valve repair and tricuspid valve repair
- Anticipated requirement for prolonged mechanical ventilation greater than 48 hours after surgery in the opinion of the investigator
- Planned concomitant carotid endarterectomy during index surgical procedure
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: CardioGard Embolic Protection Cannula
In patients assigned to the embolic protection device group, the CardioGard Embolic Protection Cannula is used instead, according to the manufacturer's instructions for use (IFU). |
The CardioGard embolic protection cannula is a device that combines the function of a standard aortic cannula with an added suction mechanism to capture debris that may result from cardiac surgery. The device is comprised of 2 hollow tubes. The first tube is the standard main forward-flow tube to return oxygenated blood to the patient's aorta. The second tube attached to an existing bypass vent port, is a novel element located posteriorly to the main tube; its function is to facilitate blood and particle suction by directing the blood back to the reservoir of the coronary bypass machine, while the retrieved embolic debris is eliminated through the filter of the venous reservoir. |
|
위약 비교기: Standard Aortic Cannula
In patients assigned to the standard cannula group, standard cannulation techniques are performed using any standard aortic cannula of the surgeon's choice |
An aortic cannula is a device that is used routinely during cardiac surgery to return oxygenated blood from the cardiac bypass machine into the patient's aorta. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of patients who experience ischemic stroke and Acute Kidney Injury (AKI)
기간: within 3 days post-randomization
|
The combined number of patients who experience clinical ischemic strokes and acute kidney injuries that have occurred within 3 days post-randomization. |
within 3 days post-randomization
|
|
Number of patients who experience of death and delirium
기간: by 7 days post-randomization
|
The combined number of patients who experience death and delirium by 7 days post-randomization (with a blanking period for delirium of days 1 and 2 post-operatively). |
by 7 days post-randomization
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Proportion of patients who experience a clinical ischemic stroke
기간: within 3 days post-randomization
|
The proportion of patients who experience a clinical ischemic stroke within 3 days will be compared between the two groups (i.e., standard cannula versus the CardioGard device). |
within 3 days post-randomization
|
|
Proportion of patients who experience a clinical ischemic stroke
기간: within 7 days post-randomization
|
The proportion of patients who experience a clinical ischemic stroke within 7 days will be compared between the two groups (i.e., standard cannula versus the CardioGard device). |
within 7 days post-randomization
|
|
Number of patients with disabling clinical stroke
기간: within 3 days post-randomization
|
Number of patients with disabling clinical stroke within 3 days post-randomization |
within 3 days post-randomization
|
|
Number of patients with disabling clinical stroke
기간: within 7 days post-randomization
|
Number of patients with disabling clinical stroke within 7 days post-randomization |
within 7 days post-randomization
|
|
Neurological outcomes assessed by National Institutes of Health Stroke Scale (NIHSS)
기간: within 3 days post-randomization
|
Neurological outcomes are assessed by National Institutes of Health stroke Scale (NIHSS) to compare the treatment outcomes of three types of service delivery models. The NIHSS is an 11-item impairment scale to evaluate neurologic outcome and degree of recovery. Each item is scored between 0 and up to 4, total score ranges 0 (normal function) and a maximum possible score 42, with higher score indicating higher level of impairment. These assessments will be administered by blinded neurology trainees or study coordinators who are certified to administer the assessments. |
within 3 days post-randomization
|
|
Neurological outcomes assessed by National Institutes of Health Stroke Scale (NIHSS)
기간: within 7 days post-randomization
|
Neurological outcomes are assessed by National Institutes of Health stroke Scale (NIHSS) to compare the treatment outcomes of three types of service delivery models. The NIHSS is an 11-item impairment scale to evaluate neurologic outcome and degree of recovery. Each item is scored between 0 and up to 4, total score ranges 0 (normal function) and a maximum possible score 42, with higher score indicating higher level of impairment. These assessments will be administered by blinded neurology trainees or study coordinators who are certified to administer the assessments. |
within 7 days post-randomization
|
|
Number of patients with disabling clinical stroke determined by modified Rankin Scale (mRS) score ≥2
기간: at baseline
|
Number of patients with disabling clinical stroke as indicated by mRS score ≥2. mRS will be assessed at baseline days. The scale runs from 0-6, running from perfect health without symptoms to death. A higher score indicates greater impairment. 0 - No symptoms.
3. - Moderate disability. Requires some help, but able to walk unassisted. 4 - Moderately severe disability. Unable to walk and attend own bodily needs without assistance. 5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6 - Dead. |
at baseline
|
|
Number of patients with disabling clinical stroke determined by modified Rankin Scale (mRS) score ≥2
기간: at 30 days
|
Number of patients with disabling clinical stroke as indicated by mRS score ≥2. mRS will be assessed at 30 days. The scale runs from 0-6, running from perfect health without symptoms to death. A higher score indicates greater impairment. 0 - No symptoms.
3. - Moderate disability. Requires some help, but able to walk unassisted. 4 - Moderately severe disability. Unable to walk and attend own bodily needs without assistance. 5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6 - Dead. |
at 30 days
|
|
Number of patients with disabling clinical stroke determined by modified Rankin Scale (mRS) score ≥2
기간: at 90 days
|
Number of patients with disabling clinical stroke as indicated by mRS score ≥2. mRS will be assessed at 90 days. The scale runs from 0-6, running from perfect health without symptoms to death. A higher score indicates greater impairment. 0 - No symptoms.
3. - Moderate disability. Requires some help, but able to walk unassisted. 4 - Moderately severe disability. Unable to walk and attend own bodily needs without assistance. 5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6 - Dead. |
at 90 days
|
|
Montreal Cognitive Assessment (MoCA) Score
기간: at baseline
|
Global cognitive screening performance will be compared between groups and collected via the Montreal Cognitive Assessment (MoCA) - blind version at presurgical baseline. The MoCA scale is used for detecting cognitive impairment. The scores range between 0 to 30 points; a score of 26 or above was considered normal. Higher values represent a better outcome. |
at baseline
|
|
Montreal Cognitive Assessment (MoCA) Score
기간: at 90 days
|
Global cognitive screening performance will be compared between groups and collected via the Montreal Cognitive Assessment (MoCA) - blind version at 90 days. The MoCA scale is used for detecting cognitive impairment. The scores range between 0 to 30 points; a score of 26 or above is considered normal. Higher values represent a better outcome. |
at 90 days
|
|
Montreal Cognitive Assessment (MoCA) Score
기간: at 12 months
|
Global cognitive screening performance will be compared between groups and collected via the Montreal Cognitive Assessment (MoCA) - blind version at 12 months. The MoCA scale is used for detecting cognitive impairment. The scores range between 0 to 30 points; a score of 26 or above is considered normal. Higher values represent a better outcome. |
at 12 months
|
|
Oral Trail Making Test - Parts A and B (executive function)
기간: at baseline
|
The Trail Making Test consists of 25 circles distributed over a sheet of paper. In Part A, the circles are numbered 1 - 25, and the patient should draw lines to connect the numbers in ascending order. In Part B, the circles include both numbers (1 - 13) and letters (A - L); as in Part A, the patient draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letters (i.e., 1-A-2-B-3-C, etc.). The patient should be instructed to connect the circles as quickly as possible, without lifting the pen or pencil from the paper. Time the patient connects the "trail." If the patient makes an error, point it out immediately and allow the patient to correct it. Results for part B are reported as the number of seconds required to complete the task; therefore, higher scores reveal greater impairment. |
at baseline
|
|
Oral Trail Making Test - Parts A and B (executive function)
기간: at 90 days post-randomization
|
The Trail Making Test consists of 25 circles distributed over a sheet of paper. In Part A, the circles are numbered 1 - 25, and the patient should draw lines to connect the numbers in ascending order. In Part B, the circles include both numbers (1 - 13) and letters (A - L); as in Part A, the patient draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letters (i.e., 1-A-2-B-3-C, etc.). The patient should be instructed to connect the circles as quickly as possible, without lifting the pen or pencil from the paper. Time the patient connects the "trail." If the patient makes an error, point it out immediately and allow the patient to correct it. Results for part B are reported as the number of seconds required to complete the task; therefore, higher scores reveal greater impairment. |
at 90 days post-randomization
|
|
Oral Trail Making Test - Parts A and B (executive function)
기간: at 12 months post-randomization
|
The trail Making Test consist of 25 circles distributed over a sheet of paper. In Part A, the circles are numbered 1 - 25, and the patient should draw lines to connect the numbers in ascending order. In Part B, the circles include both numbers (1 - 13) and letters (A - L); as in Part A, the patient draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letters (i.e., 1-A-2-B-3-C, etc.). The patient should be instructed to connect the circles as quickly as possible, without lifting the pen or pencil from the paper. Time the patient connects the "trail." If the patient makes an error, point it out immediately and allow the patient to correct it. Results for part B are reported as the number of seconds required to complete the task; therefore, higher scores reveal greater impairment. |
at 12 months post-randomization
|
|
Wechsler Adult Intelligence Scale-Revised (WAIS-R) Digit Span (auditory-verbal attention)
기간: baseline
|
The WAIS-R Digit Span test assesses short term or working memory. The examinee listens to sequences of numbers orally and then repeats them as heard, in increasing order, and in reverse order. The raw scores for "digit span" range from a minimum of 2 to a maximum of 8. For this test, the longer the span the better the cognition; therefore, the higher score is the better outcome. |
baseline
|
|
Wechsler Adult Intelligence Scale-Revised (WAIS-R) Digit Span (auditory-verbal attention)
기간: at 90 days post-randomization
|
The WAIS-R Digit Span test assesses short term or working memory. The examinee listens to sequences of numbers orally and then repeats them as heard, in increasing order, and in reverse order. The raw scores for "digit span" range from a minimum of 2 to a maximum of 8. For this test, the longer the span the better the cognition; therefore, the higher score is the better outcome. |
at 90 days post-randomization
|
|
Wechsler Adult Intelligence Scale-Revised (WAIS-R) Digit Span (auditory-verbal attention)
기간: at 12 months post-randomization
|
The WAIS-R Digit Span test assesses short term or working memory. The examinee listens to sequences of numbers orally and then repeats them as heard, in increasing order, and in reverse order. The raw scores for "digit span" range from a minimum of 2 to a maximum of 8. For this test, the longer the span the better the cognition; therefore, the higher score is the better outcome. |
at 12 months post-randomization
|
|
Wechsler Adult Intelligence Scale-Revised (WAIS-R) Digit Symbol Substitution Test (processing speed)
기간: at baseline
|
The WAIS-R Digit Symbol Substitution Test (DSST) is a paper-and-pencil cognitive test that consist of number-symbol pairs. It requires the examinee to copy, into spaces below rows of numbers, the symbols that are paired to each number. The DSST score is the number of digits coded correctly in a 90-second test period |
at baseline
|
|
Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test (verbal fluency/executive function)
기간: at baseline
|
The D-KEFS Verbal Fluency Test is comprised of three testing conditions: Letter Fluency, Category Fluency, and Category Switching. This test measures multiple aspects of verbal productivity and cognitive flexibility. It evaluates effectiveness of novel and semantic search strategies, and assesses flexibility in the implementation of word search strategies. There are three conditions in the test in which the examinee must say as many words as they can by letter, category, and category switching prompts. |
at baseline
|
|
Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test (verbal fluency/executive function)
기간: at 90 days post-randomization
|
The D-KEFS Verbal Fluency Test is comprised of three testing conditions: Letter Fluency, Category Fluency, and Category Switching. This test measures multiple aspects of verbal productivity and cognitive flexibility. It evaluates effectiveness of novel and semantic search strategies, and assesses flexibility in the implementation of word search strategies. There are three conditions in the test in which the examinee must say as many words as they can by letter, category, and category switching prompts. |
at 90 days post-randomization
|
|
Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test (verbal fluency/executive function)
기간: at 12 months post-randomization
|
The D-KEFS Verbal Fluency Test is comprised of three testing conditions: Letter Fluency, Category Fluency, and Category Switching. This test measures multiple aspects of verbal productivity and cognitive flexibility. It evaluates effectiveness of novel and semantic search strategies, and assesses flexibility in the implementation of word search strategies. There are three conditions in the test in which the examinee must say as many words as they can by letter, category, and category switching prompts. |
at 12 months post-randomization
|
|
Incidence of Delirium
기간: first 7 days post-randomization
|
The incidence of delirium will be assessed daily by the Confusion Assessment Method (3D-CAM or CAM-ICU) scale, or by the presence of a delirium adverse event, during the first 7 days post-randomization. The CAM consists of 4 features: 1-Onset, 2-Inattention, 3-Disorganized thinking, and 4-altered level of consciousness. The diagnosis of delirium by CAM is based on the presence of features 1 and 2, and either 3 or 4 and involves the presence/absence of delirium, but not its severity. Any error or behavioral observation consistent with a delirium feature means that feature is present. |
first 7 days post-randomization
|
|
Duration of Delirium
기간: first 7 days post-randomization
|
The duration of delirium will be measured as the number of days with positive CAM assessments or delirium adverse events by 7 days post-randomization. The CAM consists of 4 features: 1-Onset, 2-Inattention, 3-Disorganized thinking, and 4-altered level of consciousness. The diagnosis of delirium by CAM is based on the presence of features 1 and 2, and either 3 or 4. |
first 7 days post-randomization
|
|
Severity of Delirium
기간: first 7 days post-randomization
|
The severity of delirium will be measured during daily screening using standardized algorithms for extracting symptom severity from the 3D-CAM and CAM-ICU. |
first 7 days post-randomization
|
|
Number of Patients who experience Acute kidney injury (AKI)
기간: within -7 days post-randomization
|
Number of Patients who experience Acute kidney injury will be assessed within 7 days post-randomization. |
within -7 days post-randomization
|
|
All-cause mortality
기간: within 90 days post-randomization
|
All-cause mortality within 90 days post-randomization will be assessed. |
within 90 days post-randomization
|
|
All-cause mortality
기간: within 12 months post-randomization
|
All-cause mortality within 12-months post-randomization will be assessed. |
within 12 months post-randomization
|
|
Length of Index Hospitalization
기간: at hospital discharge, up to 30 days
|
Overall length of stay for the index hospitalization post-randomization will be measured and broken down by days spent in the ICU versus days not in the ICU. |
at hospital discharge, up to 30 days
|
|
Discharge disposition
기간: at hospital discharge, up to 30 days
|
Discharge disposition |
at hospital discharge, up to 30 days
|
|
Readmissions rates
기간: first 90 days
|
Readmission rates will be calculated for the first 90 days following randomization. Hospitalizations will be classified for all causes including for cardiovascular readmissions. |
first 90 days
|
|
Readmissions rates
기간: up to 1 year post-randomization
|
Readmission rates will be calculated for the duration of follow-up, out to 1 year. Hospitalizations will be classified for all causes including for cardiovascular readmissions. |
up to 1 year post-randomization
|
|
Days Alive out of Hospital
기간: within 90 days post-randomization
|
Days alive out of hospital and nursing/rehab facilities within 90 days after randomization |
within 90 days post-randomization
|
|
Actigraphy
기간: 7-day period prior to index surgical procedure and Day 1 post index surgical procedure through hospital discharge
|
Actigraphy data will be collected for a period of 7 days prior to the index surgical procedure. Actigraphic monitoring employs an accelerometer the size of a watch, which each study patient will wear on the wrist. Collected for participants in substudy. |
7-day period prior to index surgical procedure and Day 1 post index surgical procedure through hospital discharge
|
|
Amount of Circadian Light
기간: 7-day period prior to index surgical procedure
|
A Speck light meter will be worn as a pendant while awake for a period of 7 days prior to surgery. Light measurements from light meters used as pendants are the closest to light measurements at eye level. The light meter will also be used to monitor the total amount of circadian light received by the patient. Collected for participants in substudy. |
7-day period prior to index surgical procedure
|
|
Photopic Light Levels
기간: 7-day period prior to index surgical procedure
|
A Speck light meter will be worn as a pendant while awake for a period of 7 days prior to surgery. Light measurements from light meters used as pendants are the closest to light measurements at eye level. The light meter will also be used to calculate photopic light levels Collected for participants in substudy. |
7-day period prior to index surgical procedure
|
|
Circadian Stimulus Values
기간: 7-day period prior to index surgical procedure
|
A Speck light meter will be worn as a pendant while awake for a period of 7 days prior to surgery. Light measurements from light meters used as pendants are the closest to light measurements at eye level. The light meter will also be used to calculate circadian stimulus values, Collected for participants in substudy. |
7-day period prior to index surgical procedure
|
|
Richards-Campbell Sleep Questionnaire
기간: Day 1 post index surgical procedure through patient discharge from the ICU (average ICU stay is 3 days)
|
Patients who are able to do so will be asked to fill out the Richards-Campbell Sleep Questionnaire (RCSQ), which is a brief 2-minute questionnaire designed for patient use in the ICU. Full score range from 0-100, with higher score indicating better sleep. Collected for participants in substudy. |
Day 1 post index surgical procedure through patient discharge from the ICU (average ICU stay is 3 days)
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Annetine C. Gelijns, PhD, Icahn School of Medicine at Mount Sinai
- 수석 연구원: Steve Messe, MD, University of Pennsylvania
- 수석 연구원: Alexander Iribarne, MD, Northwell Health
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- STUDY-23-00417
- 5U01HL088942-16 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
IPD 공유 기간
De-identified study data sets must be submitted to the designated NHLBI Program Official no later than 3 years after the end of the clinical activity (final patient follow-up, etc.) or 2 years after the main paper of the trial has been published, whichever comes first. Data are prepared by the study coordinating center and sent to the designated PO for review prior to release.
IPD 공유 액세스 기준
Anyone who wishes to access the data. Any purpose. Data are available indefinitely at (Link to be included in the URL field below).
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- ICF
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .